DNA Script expanded access to its SYNTAX® enzymatic DNA synthesis platform in India through a distribution agreement with Imperial Life Sciences. The deal is designed to support decentralized, on-demand single-stranded DNA production at research sites, reducing dependence on external suppliers and improving design-build-test turnaround. Under the agreement, Imperial Life Sciences will distribute SYNTAX across India with local technical support and application expertise. DNA Script positions the platform as automating synthesis, purification, and normalization in a single workflow, enabling up to 384 oligonucleotides in parallel. For labs and early biotech developers, the move addresses a bottleneck in modern molecular tooling—faster, locally managed oligo supply can shorten both research timelines and candidate iteration cycles.